| DAY 1 | Room 3A | Room 3B | Hall 1B | Hall 1C | Room 11B - Workshop | Careers Zone, Main Exhibition Hall | |
| 08:00 |
Event Registration |
|
|
|
|
Early Career Professional Welcome
08:00 (45 mins)
Lisa Stott, Sosei Heptares
|
08:00 |
| 08:05 |
|
|
|
|
08:05 |
| 08:10 |
|
|
|
|
08:10 |
| 08:15 |
|
|
|
|
08:15 |
| 08:20 |
|
|
|
|
08:20 |
| 08:25 |
|
|
|
|
08:25 |
| 08:30 |
|
|
|
|
08:30 |
| 08:35 |
|
|
|
|
08:35 |
| 08:40 |
|
|
|
|
08:40 |
| 08:45 |
ELRIG - Annual Review - Visons & Values
08:45 (10 mins)
Melanie Leveridge, GSK
ELRIG - Equality, Diversity & Inclusion Guiding Principals
08:55 (5 mins)
Clare Viney, Vitae
ELRIG - Lifetime Achievement Award - A Career In Drug Discovery
09:00 (20 mins)
Steve Rees, AstraZeneca
|
|
|
|
|
|
08:45 |
| 08:50 |
|
|
|
|
|
08:50 |
| 08:55 |
|
|
|
|
|
08:55 |
| 09:00 |
|
|
|
|
|
09:00 |
| 09:05 |
|
|
|
|
|
09:05 |
| 09:10 |
|
|
|
|
|
09:10 |
| 09:15 |
|
|
|
|
|
09:15 |
| 09:20 |
|
|
|
|
|
09:20 |
| 09:25 |
|
|
|
|
|
09:25 |
| 09:30 |
|
|
|
|
|
09:30 |
| 09:35 |
|
|
|
|
|
09:35 |
| 09:40 |
|
|
|
|
|
09:40 |
| 09:45 |
|
|
|
|
|
09:45 |
| 09:50 |
|
|
|
|
|
09:50 |
| 09:55 |
|
|
|
|
|
09:55 |
| 10:00 |
|
|
|
|
|
10:00 |
| 10:05 |
|
|
|
|
|
10:05 |
| 10:10 |
Refreshment Break |
|
|
|
|
|
10:10 |
| 10:15 |
|
|
|
|
|
10:15 |
| 10:20 |
|
|
|
|
|
10:20 |
| 10:25 |
|
|
|
|
|
10:25 |
| 10:30 |
|
|
|
|
|
10:30 |
| 10:35 |
|
|
|
|
|
10:35 |
| 10:40 |
|
|
|
|
|
10:40 |
| 10:45 |
|
|
|
|
|
10:45 |
| 10:50 |
|
|
|
|
Gaining a career in industry: Learning tips and tricks from the inside
10:50 (60 mins)
Allan Jordan, Sygnature Discovery
|
|
10:50 |
| 10:55 |
|
10:55 |
| 11:00 |
Neuropilin-1 facilitates SARS-CoV2 cell entry and infectivity
11:00 (30 mins)
Maria Anastasina, University of Helsinki
|
Q-POCTM, a paradigm shift in rapid multiplex molecular diagnostics
11:00 (30 mins)
Jonathan OHalloran, QuantumDx
|
Discovery of risdiplam (evrysdi) - A medicine for the treatment of spinal muscular atrophy
11:00 (30 mins)
Hasane Ratni , F. Hoffmam-La Roche
|
Alzheimer’s Research UK and its support for translational research.
11:00 (30 mins)
Sara Imarisio, ARUK
|
|
11:00 |
| 11:05 |
|
11:05 |
| 11:10 |
|
11:10 |
| 11:15 |
|
11:15 |
| 11:20 |
|
11:20 |
| 11:25 |
|
11:25 |
| 11:30 |
|
11:30 |
| 11:35 |
|
11:35 |
| 11:40 |
|
11:40 |
| 11:45 |
|
11:45 |
| 11:50 |
|
|
11:50 |
| 11:55 |
|
|
11:55 |
| 12:00 |
Functional analysis of Bartonella pathogenicity factors might contribute to novel therapeutic concepts
12:00 (30 mins)
Volkhard Kempf , Goethe University of Frankfurt am Main
|
A luminescent reporter cell line for authentic SARS-CoV-2 infection and neutralising antibody activity
12:00 (30 mins)
Nick Matheson, University of Cambridge
|
mRNA Lightning platform for the discovery of selective small molecule mRNA regulatory drugs
12:00 (30 mins)
Iris Alroy, Anima Biotech
|
Identification of tool compounds targeting the SRSF1-dependent nuclear export of pathological C9ORF72-repeat transcripts
12:00 (30 mins)
Lianne Van Beek, CRL Tennore Ramesh, Sheffield Institute for Translational Neuroscience (SITraN)
|
|
|
12:00 |
| 12:05 |
|
|
12:05 |
| 12:10 |
|
|
12:10 |
| 12:15 |
|
|
12:15 |
| 12:20 |
|
|
12:20 |
| 12:25 |
|
|
12:25 |
| 12:30 |
Refreshment Break |
|
|
|
Inclusive research and experimental design
12:30 (60 mins)
Lilian Hunt, EDIS, Wellcome Trust
|
|
12:30 |
| 12:35 |
|
|
|
|
12:35 |
| 12:40 |
|
|
|
|
12:40 |
| 12:45 |
|
|
|
|
12:45 |
| 12:50 |
|
|
|
|
12:50 |
| 12:55 |
|
|
|
|
12:55 |
| 13:00 |
|
|
|
|
13:00 |
| 13:05 |
|
|
|
|
13:05 |
| 13:10 |
|
|
|
|
13:10 |
| 13:15 |
|
|
|
|
13:15 |
| 13:20 |
|
|
|
|
13:20 |
| 13:25 |
|
|
|
|
13:25 |
| 13:30 |
|
|
|
|
|
13:30 |
| 13:35 |
|
|
|
|
|
13:35 |
| 13:40 |
|
|
|
|
|
13:40 |
| 13:45 |
|
|
|
|
|
13:45 |
| 13:50 |
|
|
|
|
|
13:50 |
| 13:55 |
|
|
|
|
|
13:55 |
| 14:00 |
Targeting the human RED-SMU1 splicing complex as a basis for host-directed anti-influenza therapy
14:00 (30 mins)
Nadia Naffakh, Institut Pasteur, CNRS
|
Diagnostics for epidemics, pandemics and neglected tropical disease
14:00 (30 mins)
Emily Adams, Liverpool School of Tropical Medicine and Mologic
|
Dynamic RNAs and Structure-Guided Small Molecule Drug Discovery
14:00 (30 mins)
Isaac Kimsey, Nymirum Yang Zheng, Nymirum
|
Small molecule inhibitors of carboxylesterase Notum to potentiate Wnt signalling
14:00 (30 mins)
Nicky Willis, UCL DDI
|
Exceptional Science Presentations: How to Effectively Communicate the Value of Your Work
14:00 (45 mins)
Anita Ramanathan, Word Cortex
|
|
14:00 |
| 14:05 |
|
14:05 |
| 14:10 |
|
14:10 |
| 14:15 |
|
14:15 |
| 14:20 |
|
14:20 |
| 14:25 |
|
14:25 |
| 14:30 |
|
14:30 |
| 14:35 |
Tecan UK Ltd
2021-10-19 14:35:002021-10-19 14:40:00Europe/LondonTecan UK LtdSession at Drug Discovery 2021 After the Storm: Re-connect, Re-invent, Re-imagine
https://www.myeventflo.com/eventflo.asp?evID=2374OnlineSanj Kumar, ELRIGinfo@elrig.org |
|
14:35 |
| 14:40 |
|
|
14:40 |
| 14:45 |
Studies of the membrane-bound pyrophosphatase as a potential drug target against protist parasites
14:45 (30 mins)
Keni Vidilaseris, University of Helsinki
|
EMERGING DIAGNOSTIC TECHNOLOGIES IN CLINICAL MICROBIOLOGY
14:45 (30 mins)
Alex Van Belkum, Biomeirieux
|
Small activating RNAs from concept to Phase 2 clinical trial
14:45 (30 mins)
Vikash Reebye Nagy Habib , MiNA Therapeutics
|
Development of eIF2B modulators for the treatment of neurodegenerative disease
14:45 (30 mins)
Duncan Scott, Alborada Drug Discovery Institute, Cambridge
|
|
|
14:45 |
| 14:50 |
|
|
14:50 |
| 14:55 |
|
|
14:55 |
| 15:00 |
|
|
15:00 |
| 15:05 |
|
|
15:05 |
| 15:10 |
|
|
15:10 |
| 15:15 |
Refreshment Break |
|
|
|
|
|
15:15 |
| 15:20 |
|
|
|
|
|
15:20 |
| 15:25 |
|
|
|
|
|
15:25 |
| 15:30 |
|
|
|
|
|
15:30 |
| 15:35 |
|
|
|
|
|
15:35 |
| 15:40 |
|
|
|
|
|
15:40 |
| 15:45 |
Developing inhibitors that block adhesin-collagen interactions
15:45 (30 mins)
Dirk Linke, University of Oslo
|
Computer literate? Novel AI based reading of lateral flow devices
15:45 (30 mins)
Daniel Wise, Excalibur Healthcare
|
Drugging RNA Modifying Enzymes – METTL3 Inhibitors as a novel therapeutic strategy for Acute Myeloid Leukemia
15:45 (30 mins)
David Hardick, Storm Therapeutics Konstantinos Tzelepis , The Milner Therapeutics Institute
|
Gene editing to treat expanded CAG/CTG repeat disorders
15:45 (30 mins)
Vincent Dion, Cardiff Dementia Research Institute
|
|
|
15:45 |
| 15:50 |
|
15:50 |
| 15:55 |
|
15:55 |
| 16:00 |
|
16:00 |
| 16:05 |
|
16:05 |
| 16:10 |
|
16:10 |
| 16:15 |
|
|
16:15 |
| 16:20 |
|
16:20 |
| 16:25 |
|
16:25 |
| 16:30 |
Inhibition of bacterial virulence as an alternative to antibiotic treatment: Pseudomonas aeruginosa elastase as a target for antivirulence therapy
16:30 (30 mins)
Martin Everett, Antabio
|
How to build a mobile lab for genomic surveillance of viral outbreaks
16:30 (30 mins)
Joshua Quick, Institute of Microbiology and infection, University of Birmingham
|
X-reactivation as an approach to treating Rett Syndrome
16:30 (30 mins)
Jeannie Lee, Harvard
|
Novel Therapeutic Targets for Treatment of Neurodegeneration
16:30 (30 mins)
Paul Brennan, Oxford DDI
|
|
16:30 |
| 16:35 |
|
16:35 |
| 16:40 |
|
16:40 |
| 16:45 |
|
|
16:45 |
| 16:50 |
|
|
16:50 |
| 16:55 |
|
|
16:55 |
| 17:00 |
Networking & Posters |
|
|
|
|
|
17:00 |
| 17:05 |
|
|
|
|
|
17:05 |
| 17:10 |
|
|
|
|
|
17:10 |
| 17:15 |
|
|
|
|
|
17:15 |
| 17:20 |
|
|
|
|
|
17:20 |
| 17:25 |
|
|
|
|
|
17:25 |
| 17:30 |
|
|
|
|
|
17:30 |
| 17:35 |
|
|
|
|
|
17:35 |
| 17:40 |
|
|
|
|
|
17:40 |
| 17:45 |
|
|
|
|
|
17:45 |
| 17:50 |
|
|
|
|
|
17:50 |
| 17:55 |
|
|
|
|
|
17:55 |
| 18:00 |
|
|
|
|
|
18:00 |
| 18:05 |
|
|
|
|
|
18:05 |
| 18:10 |
|
|
|
|
|
18:10 |
| 18:15 |
|
|
|
|
|
18:15 |
| 18:20 |
|
|
|
|
|
18:20 |
| 18:25 |
|
|
|
|
|
18:25 |
| 18:30 |
|
|
|
|
|
18:30 |
| 18:35 |
|
|
|
|
|
18:35 |
| 18:40 |
|
|
|
|
|
18:40 |
| 18:45 |
|
|
|
|
|
18:45 |
| 18:50 |
|
|
|
|
|
18:50 |
| 18:55 |
|
|
|
|
|
18:55 |
| 19:00 |
|
|
|
|
|
|
19:00 |
Print